A Real-World Molecular Epidemiological Study of Non-Small-Cell Lung Cancer (NSCLC) Patients from Western India

 

 Permissions and Reprints

Abstract

Background The molecular characterization of advanced non-small-cell lung cancer (NSCLC) has unveiled genomic alterations such as EGFR gene mutations, KRAS gene mutations, ROS1 gene rearrangements, EML4-ALK rearrangements, and altered MET signaling. The objective of this molecular epidemiological study was to report the clinical, pathological, and molecular profile of NSCLC patients from western India.

Materials and Methods This real-world study of NSCLC patients was performed at a chemotherapy day-care center in western India. The clinical, pathological, and molecular data were collected from the patient's medical records after obtaining the Ethics Committee permission for the study. The study was conducted according to the ethical principles stated in the latest version of Helsinki Declaration, and the applicable guidelines for good clinical practice.

Results A total of 182 (58.7%) men and 128 (41.3%) women with a median age of 63 years (range: 22–93 years) were included in the study. Of the total 310 patients, 195 (62.9%) were nonsmokers whereas 81 (26.1%) had a past history of smoking. EGFR, EML4-ALK Fusion Gene, KRAS, ROS1 gene rearrangement, and PD-L1 were positive in 42 (22.3%), 12 (9%), 2 (28.6%), 3 (12.5%), and 3 (25%) patients, respectively. One patient had concurrent EGFR mutation along with ROS1 gene rearrangement.

Conclusion Oncogenic driver mutations are present in Indian NSCLC patients. Molecular testing should be performed for all patients of advanced NSCLC to identify those that can benefit from newer generation of targeted or immunotherapies.

Ethical Approval

The study was conducted according to the ethical principles stated in the latest version of Helsinki Declaration, and the applicable guidelines for good clinical practice.

Publication History

Article published online:
11 August 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

• References

• 1 Kris MG, Johnson BE, Kwiatkowski DJ. et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011; 29 (18, suppl): CRA7506
  CrossrefGoogle Scholar
• 2 Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008; 99 (11) 1757-1762
  CrossrefPubMedGoogle Scholar
• 3 Desai SS, Shah AS, Prabhash K, Jambhekar NA. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. Indian J Cancer 2013; 50 (02) 80-86
  CrossrefPubMedGoogle Scholar
• 4 Doval D, Prabhash K, Patil S. et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. OncoTargets Ther 2015; 8: 117-123
  Google Scholar
• 5 Mehta A, Batra U. Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung. Asian J Oncol 2017; 3: 45-49
  Article in Thieme ConnectGoogle Scholar
• 6 Rimkunas VM, Crosby KE, Li D. et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012; 18 (16) 4449-4457
  CrossrefPubMedGoogle Scholar
• 7 Chen YF, Hsieh MS, Wu SG. et al. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol 2014; 9 (08) 1171-1179
  CrossrefPubMedGoogle Scholar
• 8 Suryavanshi M, Panigrahi MK, Kumar D. et al. ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer. Lung India 2017; 34 (05) 411-414
  CrossrefPubMedGoogle Scholar
• 9 Joshi A, Pande N, Noronha V. et al. ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes. Ecancermedicalscience 2019; 13: 900
  CrossrefPubMedGoogle Scholar
• 10 Mehta A, Saifi M, Batra U, Suryavanshi M, Gupta K. Incidence of ROS1-rearranged non-small-cell lung carcinoma in India and efficacy of crizotinib in lung adenocarcinoma patients. Lung Cancer (Auckl) 2020; 11: 19-25
  Google Scholar
• 11 Dietel M, Savelov N, Salanova R. et al. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study. Lung Cancer 2019; 134: 174-179
  CrossrefPubMedGoogle Scholar